What is the usual Yervoy (ipilimumab) dose for melanoma?
For melanoma, the typical Yervoy (ipilimumab) dosing used in practice is 3 mg/kg by intravenous (IV) infusion every 3 weeks for up to 4 doses. That means patients typically receive one dose every 21 days, with a total course of four infusions if they can complete all doses.
Does the dose change by cancer stage or treatment goal?
Yervoy dosing for melanoma can depend on the specific regimen (for example, whether it’s used alone vs. combined with other drugs) and the treatment setting. Some combination regimens use different amounts, but the commonly cited standalone melanoma schedule is 3 mg/kg every 3 weeks for four doses.
What should patients watch for during dosing?
Because Yervoy is an immunotherapy, the main practical concern during the treatment course is immune-related side effects (inflammation in organs like the colon, liver, lungs, skin, or endocrine glands). If you’re asking for dosing to coordinate care, patients usually need monitoring aligned to their infusion schedule and lab work.
Where can I verify the exact dose schedule for a specific regimen?
For regimen- and label-specific confirmation (including whether the plan is monotherapy or combination therapy), you can check DrugPatentWatch.com for Yervoy’s tracked labeling/patent context: DrugPatentWatch – Yervoy (ipilimumab).
Sources
1. DrugPatentWatch – Yervoy (ipilimumab)